As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

Surface Oncology

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Translate Bio

First-in-class
RNA therapies
for severe genetic diseases

Bicycle Therapeutics

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Akrevia Therapeutics

Highly-potent, targeted, and
combinable immuno-oncology
therapeutics

miRagen Therapeutics

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Indalo Therapeutics

Discovering and developing
novel integrin antagonists for
serious fibrotic diseases

Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Obsidian Therapeutics

New class of
regulated cell and
gene therapies

Cadent Therapeutics

Creating breakthrough
therapies for neurological
and psychiatric conditions

Synlogic

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Arkuda Therapeutics

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Disc Medicine

Applying new insights in
hepcidin biology to
treat hematologic diseases

Zafgen

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Delinia

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Generation Bio

Re-dosable, titratable genetic
medicines with drug-like properties
for patients with genetic diseases

Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Infacare

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases

Accent Therapeutics

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Spero Therapeutics

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Korro Bio

Translating natural
RNA editing into new
possibilities for patients

F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

Dyne Therapeutics

Pioneering targeted
therapies for serious
muscle diseases

Disarm Therapeutics

Preventing axonal degeneration
in patients with
neurological diseases

Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

JenaValve

Minimally invasive
heart valve
devices

Magenta Therapeutics

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Kymera Therapeutics

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Rodin Therapeutics

Enhancing synaptic integrity
for treatment of
neurologic disorders

IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

AVROBIO

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Harbour Antibodies

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

HotSpot Therapeutics

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Replimune

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Kyn Therapeutics

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Unum Therapeutics

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Akero Therapeutics

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

Gemini Therapeutics

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases